- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06316856
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia
April 8, 2024 updated by: Jing Pan, Beijing GoBroad Hospital
CD5 Chimeric Antigen Receptors (CAR) T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia: a Single-center, Open-label, Non-randomized, Phase 1/2 Clinical Trial
This is a single-center, open-label, non-randomized, phase 1/2 study of anti-CD5 CAR-T cell therapy in patients with CD5+ relapsed or refractory T-cell malignancies.
A bayesian optimal interval (BOIN) 12 design will be used to explore the optimal biological dose (OBD) from starting dose level 1: 1×10^6 (±20%) to dose level 2: 2×10^6 (±20%) in three cohorts (autologous, previous-transplant-donor or newly matched donor-derived CD5 CAR T cells).
If the manufactured cells are not sufficient to meet the preassigned standard dose criteria, patients will be given infusion at a low dose level of 5×10^5 (±20%) /kg.
The primary objective is to evaluate the safety and tolerability of CD5 CAR T cell therapy in subjects, determine the OBD and recommend phase 2 dose (RP2D) in phase 1, and evaluate the efficacy of CD5 CAR T cell therapy in phase 2. The primary endpoint is the type and incidence of dose-limiting toxicity (DLT) within 28 days, and the incidence and severity of adverse events (AEs) within 30 days after CD5 CAR T-cell infusion in phase 1, the best overall response (BOR) at 3 months (± 1 week) after CD5 CAR T-cell infusion in phase 2. A total number of 54 subjects will be enrolled.
Study Overview
Status
Not yet recruiting
Conditions
Study Type
Interventional
Enrollment (Estimated)
54
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Tengyu Wang
- Phone Number: 86+18333186020
- Email: tengyu.wang@gohealtharo.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
Only patients who meet all the following criteria can be included:
- Candidates with relapse or refractory CD5+ T-cell malignancies, who have progressed after treatment with all standard therapies or been intolerant of standard care, have limited prognosis with currently available therapies and have no available curative treatment options (such as stem-cell transplantation (SCT) or chemotherapy);
- For subjects who received autologous CD5 CAR T cells, the tumor burden in peripheral blood is less than 20%, and suspending anti-neoplastic treatment for more than 2 weeks;
- Aged 1-70 years;
- No severe allergy;
- Eastern Cooperative Oncology Group (ECOG) performance status 1 score 0 to 2;
- Patients are expected to live for at least 60 days;
- CD5+ on blasts in bone marrow (BM) or cerebrospinal fluid (CSF) and tumor tissues by flow cytometry and immunohistochemistry, respectively. (Positive rate >80% by flow cytometry with less than one log difference in mean fluorescence intensity from normal T cells, or positive rate >30% positive by immunohistochemistry);
- Provide a signed informed consent before any screening procedure. Subjects who voluntarily participate in the study should have the ability to understand and sign the informed consent form and be willing to follow the study visit schedule and relevant study procedure, as specified in the protocol. Candidates aged 19-70 years need to be sufficiently conscious and able to sign the treatment consent form and voluntary consent form. Children candidates of 8-18 years old need to be sufficiently conscious and able to sign the treatment consent form and voluntary consent form and their legal guardian or patient advocate has also need to sign the treatment consent form and voluntary consent form, respectively. Children candidates of 1-7 can be recruited after the legal guardian or patient advocate has signed the treatment consent form and voluntary consent form;
- Have available allogeneic hematopoietic stem cell transplantation donor for the subject who received newly matched donor-derived CD5 CAR T cells, and is willing to perform SCT when CR is achieved.
Exclusion Criteria:
Patients with at least one of the following conditions are excluded:
- Impaired consciousness or intracranial hypertension;
- Symptomatic congestive heart failure or severe cardiac arrhythmia;
- Manifestations of severe respiratory system failure;
- Co-existence with other malignancies;
- Disseminated intravascular coagulation;
- Serum creatinine and/or blood urea nitrogen (BUN) ≥ 1.5-fold upper limit;
- Sepsis or other uncontrollable infections;
- Uncontrollable diabetes;
- Serious mental illness;
- Apparent and active intracranial lesions on cranial magnetic resonance imaging (MRI);
- Underwent organ transplantation, excepting SCT;
- Pregnant females;
- Positive test for infectious hepatitis, acquired immune deficiency syndrome (AIDS) or syphilis;
- Post-CAR SCT is not feasible in patients who plan to receive newly matched donor-derived CD5 CAR T cells;
- Inability to collect peripheral blood mononuclear cells (PBMC) or no frozen PBMC available for CAR T cell manufacturing.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Autologous CD5 CAR T-cells
After a lymphodepleting regimen, the patients will receive autologous CD5 CAR T-cell infusion.
|
Peripheral blood mononuclear cells for the production of CD5 CAR T-cells from patients.
|
Experimental: Newly matched donor-derived CD5 CAR T-cells
After a lymphodepleting regimen, the patients will receive newly matched donor-derived CD5 CAR T-cell infusion.
|
Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from newly matched donors.
|
Experimental: Prior stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells
After a lymphodepleting regimen, the patients will receive prior SCT donor-derived CD5 CAR T-cell infusion.
|
Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from previous SCT donors.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1-The incidence and type of dose-limiting toxicity (DLT)
Time Frame: 28 days after CD5 CAR T cell infusion
|
The number of patients experiencing dose-limiting toxicity (DLT) will be evaluated and the type of DLT will be recorded.
|
28 days after CD5 CAR T cell infusion
|
Phase 1-The incidence and severity of adverse events (AEs)
Time Frame: 30 days after CD5 CAR T cell infusion
|
The number of patients experiencing adverse events (AEs) and the severity of AEs will be evaluated.
|
30 days after CD5 CAR T cell infusion
|
Phase 2-Antitumor effect
Time Frame: 3 months (± 1 week) after CD5 CAR T infusion
|
Assessment of best overall response (BOR) rate.
BOR rate is the percentage of patients with the best overall response in complete response (CR), complete response with incomplete hematological recovery (CRi) or partial response (PR) based on the National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2023 of Acute Lymphoblastic Leukemia.
|
3 months (± 1 week) after CD5 CAR T infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1-Objective response rate (ORR)
Time Frame: 30 days after CD5 CAR T cell infusion
|
Objective response rate (ORR) is the percentage of subjects who have achieved CR, CRi or PR based on the National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2023 of Acute Lymphoblastic Leukemia.
|
30 days after CD5 CAR T cell infusion
|
Phase 1-Pharmacokinetics of CD5 CAR T cells
Time Frame: Up to 2 years after CD5 CAR T cell infusion
|
The proliferation and survival of CAR T cells will be measured by flow cytometry and quantitative polymerase chain reaction (qPCR).
|
Up to 2 years after CD5 CAR T cell infusion
|
Phase 1-The incidence and severity of adverse events (AEs).
Time Frame: From 30 days to 2 years after CD5 CAR T cell infusion
|
The number of patients experiencing adverse events (AEs) and the severity of AEs will be evaluated.
|
From 30 days to 2 years after CD5 CAR T cell infusion
|
Phase 1-Best overall response (BOR) rate.
Time Frame: 3 months (± 1 week) after CD5 CAR T cell infusion
|
BOR rate is the percentage of patients with the best overall response in CR, CRi or PR based on the National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2023 of Acute Lymphoblastic Leukemia.
|
3 months (± 1 week) after CD5 CAR T cell infusion
|
Phase 2-Objective response rate (ORR)
Time Frame: 1 months and 3 months after CD5 CAR T cell infusion
|
Objective response rate (ORR) is the percentage of subjects who have achieved CR, CRi or PR based on the National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2023 of Acute Lymphoblastic Leukemia.
|
1 months and 3 months after CD5 CAR T cell infusion
|
Phase 2- The incidence and severity of AEs
Time Frame: Up to 2 years
|
The number of patients experiencing adverse events (AEs) and the severity of AEs will be evaluated.
|
Up to 2 years
|
Phase 2- Progression free survival (PFS)
Time Frame: Up to 2 years
|
Progression-free survival (PFS) is defined as the time from the initial CD5 CAR T cell infusion to the date of progression or death for any cause.
|
Up to 2 years
|
Phase 2- Overall survival (OS).
Time Frame: Up to 2 years
|
Overall survival (OS) is defined the time from the initial CD5 CAR T cell infusion to death for any cause.
|
Up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
April 20, 2024
Primary Completion (Estimated)
December 31, 2025
Study Completion (Estimated)
June 30, 2026
Study Registration Dates
First Submitted
March 10, 2024
First Submitted That Met QC Criteria
March 15, 2024
First Posted (Actual)
March 19, 2024
Study Record Updates
Last Update Posted (Actual)
April 9, 2024
Last Update Submitted That Met QC Criteria
April 8, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BJGBYY-IIT-LCYJ-2024-002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Lymphoblastic Leukemia, in Relapse
-
Institut Paoli-CalmettesINATHERYSRecruitingAcute Lymphoblastic Leukemia, in Relapse | Acute Myeloid Leukemia, in Relapse | Mixed Phenotype Acute Leukemia | Acute Lymphoblastic Leukemia Recurrent | Acute Myeloid Leukaemia RecurrentFrance
-
Federal Research Institute of Pediatric Hematology...RecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia, in Relapse | Non-hodgkin Lymphoma | High Risk Acute Myeloid Leukemia | High Risk Acute Lymphoblastic Leukemia | Acute Biphenotypic Leukemia in RelapseRussian Federation
-
Beijing Boren HospitalRecruitingAcute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic LeukemiaChina
-
Andrew E. Place, MDUniversity of Colorado, Denver; AbbVie; Boston Children's Hospital; Gateway for... and other collaboratorsRecruitingAcute Lymphoblastic Leukemia, in Relapse | Therapy-Related Myelodysplastic Syndrome | Acute Leukemia of Ambiguous Lineage | Acute Leukemia of Ambiguous Lineage in Relapse | Myelodysplastic Syndromes, Previously Treated | Acute Lymphoblastic Leukemia With Failed Remission | Myelodysplastic Syndromes... and other conditionsUnited States
-
Group for Research in Adult Acute Lymphoblastic...AmgenUnknownAcute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia With Failed RemissionFrance
-
University of BirminghamAstraZeneca; Cancer Research UKTerminatedAcute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia RecurrentUnited Kingdom, Denmark, Netherlands
-
St. Jude Children's Research HospitalActive, not recruitingAcute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, RefractoryUnited States
-
Beijing Boren HospitalRecruitingAcute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic LeukemiaChina
-
Assistance Publique - Hôpitaux de ParisRecruitingAcute Lymphoblastic Leukemia, in Relapse | B Acute Lymphoblastic LeukemiaFrance
-
Chongqing Precision Biotech Co., LtdRecruitingAcute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic LeukemiaChina
Clinical Trials on Autologous CD5 CAR T-cells
-
iCell Gene TherapeuticsPeking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.RecruitingT-cell Acute Lymphoblastic Leukemia | T-cell Non-Hodgkin LymphomaChina
-
Xuanwu Hospital, BeijingBaoding Children's HospitalRecruitingT-cell Acute Lymphoblastic LeukemiaChina
-
The First Affiliated Hospital of Nanchang UniversityUnknownRelapsed or Refractory Multiple MyelomaChina
-
Hebei Senlang Biotechnology Inc., Ltd.Hebei Yanda Ludaopei Hospital; Beijing Lu Daopei HospitalRecruitingLymphoma | Leukemia | Multiple Myeloma of Bone (Diagnosis)China
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...RecruitingT-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | T-non-Hodgkin LymphomaUnited States
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.The First People's Hospital of Hefei; Hefei Binhu HospitalUnknownMalignant Glioma of Brain | Gastric Carcinoma | Colorectal CarcinomaChina
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.The First People's Hospital of Hefei; Hefei Binhu HospitalUnknownHepatocellular Carcinoma | Non-small Cell Lung Cancer | Pancreatic Carcinoma | Triple-Negative Invasive Breast CarcinomaChina
-
Hebei Senlang Biotechnology Inc., Ltd.The Second Hospital of Hebei Medical UniversityUnknown
-
Changhai HospitalCARsgen Therapeutics Co., Ltd.UnknownPancreatic Adenocarcinoma | Advanced Gastric AdenocarcinomaChina
-
Hebei Senlang Biotechnology Inc., Ltd.Hebei Yanda Ludaopei HospitalActive, not recruitingAcute Lymphocytic LeukemiaChina